Sofituzumab vedotin
- Generic Name
- Sofituzumab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1418200-58-4
- Unique Ingredient Identifier
- 2X3CKG601L
- Background
Sofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01335958
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath